The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
 
Paolo Tarantino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Gilead Sciences; Lilly; Novartis
Research Funding - AstraZeneca
 
Do Lee
No Relationships to Disclose
 
Julia Foldi
No Relationships to Disclose
 
Pamela R. Soulos
No Relationships to Disclose
 
Cary Philip Gross
Research Funding - AstraZeneca (Inst); Genentech; Johnson & Johnson (Inst)
 
Thomas Grinda
Consulting or Advisory Role - AstraZeneca; Cancerologie-pratique
Research Funding - Amgen
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer
Other Relationship - Philippe Foundation
 
Eric P. Winer
Research Funding - Genentech (Inst)
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - Olema Pharmaceuticals
 
Ian E. Krop
Employment - PureTech (I)
Leadership - PureTech (I)
Stock and Other Ownership Interests - PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi
 
Maryam B. Lustberg
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; Novartis; Osmol Therapeutics; Pfizer; Seagen
Speakers' Bureau - Lilly
Other Relationship - Cynosure/Hologic
 
Sarah L Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)